Clinical Management of Cavernous Malformations
- PMID: 29046973
- DOI: 10.1007/s11886-017-0931-1
Clinical Management of Cavernous Malformations
Abstract
Purpose of review: This study aims to review the current epidemiology and clinical management of patients with cavernous malformations (CM).
Recent findings: Hemorrhage is the most feared complication and leads to morbidity in patients with CM. Multiple studies including three meta-analyses have provided useful estimates of hemorrhage risk, but have failed to identify a modifiable risk factor for prevention of cavernous malformation related hemorrhage. In treating the CM itself, surgical risk is weighed against the natural history. However, accumulating knowledge regarding the roles of CCM 1, 2, and 3 genes has led to the discovery of potential therapeutic targets. The risk of future hemorrhage in patients with CM is highest in those who have had previously clinical hemorrhages. Estimated risks are helpful in counseling patients and comparing to the risk of surgery. Future clinical trials of candidate medications are likely to target those patients with prior clinical hemorrhage in whom the surgical risk is deemed high.
Keywords: Cavernous angioma; Cavernous malformation; Epidemiology; Management; Treatment.
Similar articles
-
Relevance of CCM gene polymorphisms for clinical management of sporadic cerebral cavernous malformations.J Neurol Sci. 2017 Sep 15;380:31-37. doi: 10.1016/j.jns.2017.06.043. Epub 2017 Jun 29. J Neurol Sci. 2017. PMID: 28870584
-
High-throughput sequencing of the entire genomic regions of CCM1/KRIT1, CCM2 and CCM3/PDCD10 to search for pathogenic deep-intronic splice mutations in cerebral cavernous malformations.Eur J Med Genet. 2017 Sep;60(9):479-484. doi: 10.1016/j.ejmg.2017.06.007. Epub 2017 Jun 20. Eur J Med Genet. 2017. PMID: 28645800
-
Novel CCM1 (KRIT1) Mutation Detection in Brazilian Familial Cerebral Cavernous Malformation: Different Genetic Variants in Inflammation, Oxidative Stress, and Drug Metabolism Genes Affect Disease Aggressiveness.World Neurosurg. 2020 Jun;138:535-540.e8. doi: 10.1016/j.wneu.2020.02.119. Epub 2020 Feb 28. World Neurosurg. 2020. PMID: 32113992
-
Molecular diagnosis in cerebral cavernous malformations.Neurologia. 2017 Oct;32(8):540-545. doi: 10.1016/j.nrl.2015.07.001. Epub 2015 Aug 21. Neurologia. 2017. PMID: 26304651 Review. English, Spanish.
-
Cranial Cavernous Malformations: Natural History and Treatment.Stroke. 2018 Apr;49(4):1029-1035. doi: 10.1161/STROKEAHA.117.017074. Epub 2018 Mar 13. Stroke. 2018. PMID: 29535273 Review. No abstract available.
Cited by
-
KRIT1: A Traffic Warden at the Busy Crossroads Between Redox Signaling and the Pathogenesis of Cerebral Cavernous Malformation Disease.Antioxid Redox Signal. 2023 Mar;38(7-9):496-528. doi: 10.1089/ars.2021.0263. Epub 2022 Nov 1. Antioxid Redox Signal. 2023. PMID: 36047808 Free PMC article. Review.
-
Vertigo due to cerebellar cavernous malformation: A case report.Radiol Case Rep. 2022 Jul 27;17(10):3495-3500. doi: 10.1016/j.radcr.2022.06.088. eCollection 2022 Oct. Radiol Case Rep. 2022. PMID: 35912296 Free PMC article.
-
Removal of a temporal lobe cavernous angioma to control epileptic seizures in a patient with tuberous sclerosis complex.Heliyon. 2020 Jun 23;6(6):e04229. doi: 10.1016/j.heliyon.2020.e04229. eCollection 2020 Jun. Heliyon. 2020. PMID: 32613114 Free PMC article.
-
Use of balloon angioplasty for patients with intracranial large atherosclerotic acute ischemic stroke and cerebral cavernous malformation: a case report.Front Neurol. 2025 Jan 22;16:1500451. doi: 10.3389/fneur.2025.1500451. eCollection 2025. Front Neurol. 2025. PMID: 39911453 Free PMC article.
-
Multidrug-Loaded Lipid Nanoemulsions for the Combinatorial Treatment of Cerebral Cavernous Malformation Disease.Biomedicines. 2023 Feb 7;11(2):480. doi: 10.3390/biomedicines11020480. Biomedicines. 2023. PMID: 36831015 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials